Investors Urged to Act as Class Action Against ImmunityBio, Inc. Unfolds

In a significant development for investors of ImmunityBio, Inc. (NASDAQ: IBRX), the national law firm Berger Montague PC has initiated a class action lawsuit on behalf of individuals who purchased or acquired shares of the company between January 19, 2026, and March 24, 2026. With a growing concern surrounding the company’s performance and its management's statements, investors are encouraged to be informed about their rights and the implications of this legal action.

Background of the Case

ImmunityBio, headquartered in San Diego, California, specializes in innovative cancer immunotherapies and vaccines, prominently featuring its Anktiva platform. As a clinical-stage biopharmaceutical firm, it has captured the attention of investors for its promising yet challenging journey within a competitive market.

However, the lawsuit highlights critical allegations that have emerged, suggesting that the disclosures made by ImmunityBio's Chief Scientific and Medical Officer, Patrick Soon-Shiong, regarding the Anktiva platform were significantly exaggerated. Furthermore, there are claims that previous assertions related to the company’s operations, business prospects, and performance did not rest on reasonable grounds, thereby misleading investors who placed their trust in the company's growth potential.

These serious allegations have reportedly resulted in a sudden and drastic downturn for ImmunityBio’s stock, as shares plummeted more than 21% within a single trading session, leading to substantial financial losses for many investors.

Understanding Your Rights

For those who acquired ImmunityBio securities during the specified class period, there is a pressing deadline to consider participation as a lead plaintiff representative for the class, which is set for May 26, 2026. Affected investors are urged to take proactive steps to understand their legal rights and discuss the situation further with qualified counsel.

To learn more about the class action proceedings or to inquire about your eligibility, it is advised to connect with the representatives from Berger Montague. Legal professionals Andrew Abramowitz and Caitlin Adorni can be reached at their respective contact numbers provided in the lawsuit press release, illustrating the commitment of the firm to ensure that affected investors have the right information and support.

About Berger Montague

Berger Montague has established itself as a leader in complex civil litigation and class actions across the United States. With a formidable track record, the firm has secured over $2.4 billion in post-trial judgments in 2025 alone, affirming its expertise in a wide range of legal fields tendered to safeguarding an extensive clientele. With pertinent experience in securities class actions, the firm stands ready to advocate for investors seeking justice against corporate misconduct.

In light of these developments, ImmunityBio investors are encouraged not just to remain informed but also to actively pursue their options moving forward. This lawsuit serves as a reminder of the importance of vigilance in the financial markets, especially within sectors as dynamic and sensitive as biotechnology.

Ensuring you are represented and informed is crucial. As the situation unfolds, it is recommended that investors keep abreast of further announcements and continue to seek guidance from trusted legal experts to navigate the complexities of securities litigation. Reporting misconduct, understanding your rights, and asserting them with the help of professionals like those at Berger Montague could pave the way for recovery and appropriate redress.